Skip to main content

Find Drugs & Conditions

Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products.

FDA Approves Myhibbin (mycophenolate mofetil) Oral Suspension for Prophylaxis of Organ Rejection

WOBURN, Mass. May 6, 2024 – Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose forms and formulations of products...

Feds Announce New Measures to Monitor, Prevent Bird Flu

H5N1 avian flu is now infecting U.S. dairy cows and the federal government on Friday announced a myriad of initiatives aimed at preventing the virus' mutation...

Implantable Continuous Flow Device Feasible for Small Children With Severe Systolic Heart Failure

The Jarvik 2015 left ventricular assist device (LVAD) seems promising as an implantable continuous flow device for small children with severe systolic...

Clinical Practice Guideline Developed for Age-Related Hearing Loss

In a clinical practice guideline issued by the American Academy of Otolaryngology-Head and Neck Surgery Foundation and published online April 30 in Otolaryngology-Head...

Large Language Models Fall Short in Breast Imaging Classification

Large language models (LLMs) appear to fall short in classification of breast imaging, which can have a negative impact on clinical management, according...

Cardiovascular, Kidney, and Metabolic Syndrome Highly Prevalent in the U.S.

Cardiovascular, kidney, and metabolic (CKM) syndrome is highly prevalent in the United States, with more than 90 percent of adults meeting the criteria...

His Cancer Journey Shows Health Dangers Firefighters Face

For 14 years, David Perez fought fires in South Florida, thinking he was in peak physical shape. Then a routine physical turned up anomalies in his blood...

Baby Girl Born Deaf Gains Hearing After Gene Therapy

Opal Sandy was born into a world she could not hear.  The British baby girl, now 18 months old, had a rare genetic condition called auditory neuropathy...

Cancer Patients Often Face Medical Debt, Even With Insurance

When cancer strikes, you could easily go into debt, even with health insurance in place, according to a new survey from the American Cancer Society. The...

There's a New Set of COVID Variants Called FLiRT: What You Need to Know

The virus behind COVID has mutated again, this time producing variants nicknamed FLiRT, the U.S. Centers for Disease Control and Prevention (CDC) has reported. The...

Bayer to Unveil Late-Breaking Data from Phase III OASIS 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer will present detailed results from the pivotal Phase III studies OASIS 1 and 2 evaluating the efficacy and safety of the investigational compound...

Faster Approach for Starting Extended-Release Naltrexone to Treat Opioid Use Disorder Shown Effective

Starting people with opioid use disorder on extended-release, injectable naltrexone (XR-naltrexone) within five to seven days of seeking treatment is more...

Read more news...

Recently Added

Recently added consumer and prescribing information: Myhibbin, Rezenopy, Libervant, Beqvez, Xolremdi, Pivya, Xromi, Risvan, Voydeya, Winrevair

For Consumers

For Professionals

For Researchers

Latest FDA New Drug Approvals

  • Myhibbin Myhibbin (mycophenolate mofetil) is an antimetabolite immunosuppressant used for the prophylaxis of organ rejection.
  • Libervant Libervant (diazepam) is a buccal film formulation of the benzodiazepine diazepam that may be given to treat children aged 2 to 5 years with...
  • Xolremdi Xolremdi (mavorixafor) is a CXC chemokine receptor 4 (CXCR4) antagonist indicated in patients 12 years of age and older with WHIM syndrome...

More FDA approvals

Drugs in Development (Not yet approved)

  • Yutrepia Yutrepia (treprostinil) is an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) to...

More drugs in development